middle.news
Amplia and Lilly Collaborate on Lung Cancer Trial Combining Narmafotinib and Olomorasib
8:22am on Tuesday 4th of August, 2026 AEST
•
Healthcare
Read Story
Amplia and Lilly Collaborate on Lung Cancer Trial Combining Narmafotinib and Olomorasib
8:22am on Tuesday 4th of August, 2026 AEST
Key Points
Clinical Trial Collaboration with Eli Lilly signed
Phase 1b/2b trial for NSCLC to start late 2026
Narmafotinib targets resistance to KRAS G12C inhibitors
Expands Amplia’s clinical focus into $31B NSCLC market
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE